Displaying drugs 14576 - 14600 of 15439 in total
N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
Experimental
p-Fluorofentanyl
p-Fluorofentanyl is an opioid analgesic being an analogue of fentanyl developed by Janssen Pharmaceutica in the 1960s. p-Fluorofentanyl was sold briefly on the US black market in the early 1980s, before the introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs...
Illicit
REP8839
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
Anti-SARS-CoV-2 IgY
Anti-SARS-CoV-2 IgY are chicken egg antibodies to SARS-CoV-2 which have the potential to provide temporary protection against the virus when administered as intranasal drops. To create these antibodies, chickens are injected in the chest with the spike protein, which is the surface protein of SARS-CoV-2; this results in an immune...
Investigational
Matched Description: … From there, the chicken antibodies are harvested from the egg yolks of the eggs laid by these chickens and ... antibodies are currently being investigated against COVID-19 in the trial NCT04567810 (Safety, Tolerability, and …
3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
Experimental
(2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
Experimental
(R)-Praziquantel
(R)-Praziquantel is under investigation in clinical trial NCT02271984 (Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers).
Investigational
Lorcainide
Experimental
Simfibrate
Experimental
Meptazinol
Experimental
VSF-173
VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive...
Investigational
Matched Description: … It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression …
CHF 4227
CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used...
Investigational
Matched Description: … The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone …
Vapitadine
Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
Investigational
Matched Description: … is developing as a treatment for allergic reactions of the skin, such as those associated with hives and …
MK-0354
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
Matched Description: … orally administered drug candidate under development by Merck for the treatment of atherosclerosis and …
Avasopasem manganese
Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.[L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19.
Investigational
Matched Description: … [L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis …
rhGAD65
rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.
Investigational
CG7870
CG7870 is an oncolytic virus therapy for prostate cancer. It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Investigational
LC16M8
LC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines. It is the only attenuated vaccine to be licensed for use in humans to prevent smallpox infection.
Investigational
PDPSC18
PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
Investigational
Displaying drugs 14576 - 14600 of 15439 in total